Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report ; volume:23 ; number:1 ; day:30 ; month:10 ; year:2023 ; pages:1-6 ; date:12.2023
BMC infectious diseases ; 23, Heft 1 (30.10.2023), 1-6, 12.2023
- Creator
-
Mulindwa, Frank
Castelnuovo, Barbara
Brusselaers, Nele
Bollinger, Robert
Yendewa, George
Amutuhaire, Willington
Mukashaka, Claudine
Schwarz, Jean-Marc
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12879-023-08712-z
- URN
-
urn:nbn:de:101:1-2024011708314942360618
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:22 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mulindwa, Frank
- Castelnuovo, Barbara
- Brusselaers, Nele
- Bollinger, Robert
- Yendewa, George
- Amutuhaire, Willington
- Mukashaka, Claudine
- Schwarz, Jean-Marc
- SpringerLink (Online service)
Other Objects (12)
Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
Dolutegravir: Nutzenbewertung gemäß § 35a SGB V
Creation of a long-acting nanoformulated dolutegravir
Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
Modifying dolutegravir to PrEPare for long life
Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment
Dolutegravir (HIV-Infektion) : Addendum zum Auftrag A17-11
Dolutegravir (HIV-Infektion) : Nutzenbewertung gemäß § 35a SGB V
Dolutegravir/Abacavir/ Lamivudin: Nutzenbewertung gemäß § 35a SGB V
Substance use, Unlike Dolutegravir, is Associated with Mood Symptoms in People Living with HIV
Dolutegravir/Lamivudin (HIV-Infektion) : Nutzenbewertung gemäß § 35a SGB V
Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
Dolutegravir: Nutzenbewertung gemäß § 35a SGB V
Creation of a long-acting nanoformulated dolutegravir
Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
Modifying dolutegravir to PrEPare for long life
Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment
Dolutegravir (HIV-Infektion) : Addendum zum Auftrag A17-11
Dolutegravir (HIV-Infektion) : Nutzenbewertung gemäß § 35a SGB V
Dolutegravir/Abacavir/ Lamivudin: Nutzenbewertung gemäß § 35a SGB V
Substance use, Unlike Dolutegravir, is Associated with Mood Symptoms in People Living with HIV
Dolutegravir/Lamivudin (HIV-Infektion) : Nutzenbewertung gemäß § 35a SGB V
Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
Dolutegravir: Nutzenbewertung gemäß § 35a SGB V
Creation of a long-acting nanoformulated dolutegravir
Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
Modifying dolutegravir to PrEPare for long life
Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment
Dolutegravir (HIV-Infektion) : Addendum zum Auftrag A17-11
Dolutegravir (HIV-Infektion) : Nutzenbewertung gemäß § 35a SGB V
Dolutegravir/Abacavir/ Lamivudin: Nutzenbewertung gemäß § 35a SGB V
Substance use, Unlike Dolutegravir, is Associated with Mood Symptoms in People Living with HIV